Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

210 results
Display

Lovastatin derivative dehydrolovastatin ameliorates ulcerative colitis in mice by suppressing NF-κB and inflammatory cytokine expression

Zhang X, Deng QH, Deng JH, Wang SJ, Chen Q

Ulcerative colitis (UC) is associated with intestinal immune imbalance and inflammatory response. Because dehydrolovastatin (DLVT), a derivative of lovastatin, has been recently shown to inhibit inflammation and relieve immune arthritis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Atypical Extraintestinal Manifestation in a Child with Ulcerative Colitis: Cutaneous Leukocytoclastic Vasculitis

Oh SJ, Choi Y, Kim CR, Park JH, Lee JH, Lee DY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice

Ghafouri Z, Seyyedian , Nikbakht J, Kouhsari E, Bayat S, Zargar H, Houshmand

BACKGROUND/AIMS: Ulcerative colitis (UC) is a type of inflammatory bowel disease that mainly involves the colon. Thus far, glucocorticoids and amino-salicylate have been the main treatment. METHODS: To assess drugs with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study

Han M, Jung YS, Cheon JH, Park S

PURPOSE: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with ulcerative colitis (UC) are extremely limited, especially in the Asian population. We compared clinically important...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Polypharmacy is a risk factor for disease flare in adult patients with ulcerative colitis: a retrospective cohort study

Wang J, Nakamura T, Tuskey AG, Behm BW

BACKGROUND/AIMS: Polypharmacy is a common clinical problem with chronic diseases that can be associated with adverse patient outcomes. The present study aimed to determine the prevalence and patient-specific characteristics associated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan

Yanagi T, Ushijima K, Koga H, Tomomasa T, Tajiri H, Kunisaki R, Isihige T, Yamada H, Arai K, Yoden A, Aomatsu T, Nagata S, Uchida K, Ohtsuka Y, Shimizu T

BACKGROUND/AIMS: Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tacrolimus in pediatric ulcerative colitis: does it have a role?

Kim S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Anti-Le(bH) Antibody Identified in a Patient with Ulcerative Colitis

Hong J, Kim MS, Kim JS, Park H, Ko DH, Hwang SH, Oh HB

A 67-year-old man previously diagnosed with ulcerative colitis complained of difficulty in defecation and underwent balloon dilatation of rectum, but the procedure failed. The patient was transferred to a surgical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diffuse Involvement of Primary Colorectal Lymphoma Simulating Ulcerative Colitis

Kim JY, Chang SH, Kim HS, Joo M

Diffuse involvement of colorectal lymphoma masquerading as colitis is a very rare presentation of primary colorectal lymphoma. Detecting occult lymphoma is difficult in the setting of diffuse colonic involvement with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis

Jun YK, Chun J, Kang EA, Lee HJ, Im JP, Kim JS

Anti-tumor necrosis factor (anti-TNF) is an effective biological agent for the treatment of moderate-to-severe active ulcerative colitis (UC) refractory to conventional therapy. On the other hand, anti-TNF therapy is strongly...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study

Hibi T, Motoya S, Ashida T, Sai S, Sameshima , Nakamura S, Maemoto A, Nii M, Sullivan B, Gasser Jr , Suzuki Y

BACKGROUND/AIMS: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis

Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, Geddes J, Goodwin G, Collins G, Travis S, Peters M

BACKGROUND/AIMS: TrueColours ulcerative colitis (TCUC) is a comprehensive web-based program that functions through email, providing direct links to questionnaires. Several similar programs are available, however patient perspectives are unexplored. METHODS: A...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study

Park SK, Park SH, Eun CS, Seo GS, Im JP, Kim TO, Park DI

BACKGROUND/AIMS: A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia G, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu , Yang SK, Ouyang Q, Geary R, De Silva J, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW, on behalf of the Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis

The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis

Yoon H

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Mucus Barrier in Ulcerative Colitis Pathogenesis Using Proteomics

Lee CM

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature

Choi YS, Kim JK, Kim WJ, Kim MJ

Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis

Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T

BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis

Park M, Lee J, Kang SB, Park Y

Mesalazine suppositories are widely used to treat ulcerative colitis and have a guaranteed safety profile, but although rare, they can cause pulmonary toxicity. A 35-year-old woman with ulcerative colitis was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T

BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr